BNXT Stock Overview
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, the United States, and Canada.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
BioNxt Solutions Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.46 |
52 Week High | CA$0.75 |
52 Week Low | CA$0.25 |
Beta | 0.61 |
1 Month Change | -26.98% |
3 Month Change | -13.21% |
1 Year Change | -35.21% |
3 Year Change | -82.96% |
5 Year Change | n/a |
Change since IPO | -54.00% |
Recent News & Updates
Shareholder Returns
BNXT | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | -14.8% | 4.7% | 0.2% |
1Y | -35.2% | 39.5% | 9.0% |
Return vs Industry: BNXT underperformed the Canadian Pharmaceuticals industry which returned 30.4% over the past year.
Return vs Market: BNXT underperformed the Canadian Market which returned 9.3% over the past year.
Price Volatility
BNXT volatility | |
---|---|
BNXT Average Weekly Movement | 12.8% |
Pharmaceuticals Industry Average Movement | 13.5% |
Market Average Movement | 8.6% |
10% most volatile stocks in CA Market | 18.5% |
10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: BNXT's share price has been volatile over the past 3 months.
Volatility Over Time: BNXT's weekly volatility (13%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | Hugh A. Rogers | https://www.bionxt.com |
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, the United States, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors.
BioNxt Solutions Inc. Fundamentals Summary
BNXT fundamental statistics | |
---|---|
Market cap | CA$52.45m |
Earnings (TTM) | -CA$12.62m |
Revenue (TTM) | CA$388.85k |
129.3x
P/S Ratio-4.0x
P/E RatioIs BNXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BNXT income statement (TTM) | |
---|---|
Revenue | CA$388.85k |
Cost of Revenue | CA$144.27k |
Gross Profit | CA$244.59k |
Other Expenses | CA$12.86m |
Earnings | -CA$12.62m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.12 |
Gross Margin | 62.90% |
Net Profit Margin | -3,244.46% |
Debt/Equity Ratio | -121.0% |
How did BNXT perform over the long term?
See historical performance and comparison